We're taking a closer look at Medtronic today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -0.4% compared to 1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
-
Medtronic has moved 8.3% over the last year compared to 24.0% for the S&P 500 -- a difference of -15.8%
-
MDT has an average analyst rating of buy and is -9.0% away from its mean target price of $90.19 per share
-
Its trailing 12 month earnings per share (EPS) is $3.08
-
Medtronic has a trailing 12 month Price to Earnings (P/E) ratio of 26.6 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $5.45 and its forward P/E ratio is 15.1
-
MDT has a Price to Earnings Growth (PEG) ratio of 4.78, which shows the company is potentially overvalued when we factor growth into the price to earnings calculus.
-
The company has a Price to Book (P/B) ratio of 2.12 in contrast to the S&P 500's average ratio of 2.95
-
Medtronic is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
-
Medtronic has on average reported free cash flows of $5.16 Billion over the last four years, during which time they have grown by an an average of 2.2%